Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 13 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/7/2007 First Published: 1/26/2003


1.		Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) Versus Docetaxel as Second-Line Therapy in Patients With Progressive Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CTI-PGT302 CWRU-CTI-1503, NCT00054184

Last Modified: 1/30/2007 First Published: 1/26/2003


2.		Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) Versus Gemcitabine or Vinorelbine in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CTI-PGT304 NCT00054197

Last Modified: 1/22/2008 First Published: 1/26/2003


3.		Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CTI-PGT303 NCT00054210

Last Modified: 6/2/2008 First Published: 4/20/2006


4.		Phase III Randomized Study of Paclitaxel Poliglumex Versus Paclitaxel in Women With Chemotherapy-Naïve Stage IIIB or IV Non-Small Cell Lung Cancer and Performance Status 2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				CTI-PGT305 CTI-PIONEER, NCT00269828

Last Modified: 7/1/2002 First Published: 6/1/2001


5.		Phase I/II Study of CT-2103 in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Not specified				NCI, Pharmaceutical / Industry				MSKCC-01024 CTI-1071, NCI-G01-1947, NCT00017017

Last Modified: 2/19/2008 First Published: 9/1/2002


6.		Phase II Study of Polyglutamate Paclitaxel (CT-2103) as Third-Line Treatment in Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				GOG-0186C NCT00045682, GOG-0186C


7.		Phase II CT-2103/Carboplatin in Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				PGT201 NCT00069901

Last Modified: 7/10/2007 First Published: 12/9/2005


8.		Phase II Study of Paclitaxel Poliglumex (CT-2103; Xyotax™) and Capecitabine in Patients With Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCCTG-N0437 N0437, NCT00265733


9.		Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				PCa-X-02 03-0192-05, NCT00446836

Last Modified: 10/14/2008 First Published: 4/6/2007


10.		Phase II Study of Paclitaxel Poliglumex and Transdermal Estradiol in Patients With Androgen-Independent Stage IV Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				18 and over				NCI				OHSU-2656 SOL-06048-L, NCT00459810

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute